Navigation Links
Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment

WASHINGTON, April 4, 2007-Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that the use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone. The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

The data monitoring committee overseeing the trial (known as E4A03) recommended that the survival results from a recent interim analysis be made public because of early differences being seen in overall survival rates. Researchers found that patients in the study who received low-dose dexamethasone and lenalidomide had a one-year survival of 96 percent compared to 86 percent for patients treated with the standard-dose of dexamethasone and lenalidomide. In addition, there were fewer side effects associated with the low-dose dexamethasone and lenalidomide. Detailed results from this trial will be presented at the American Society of Clinical Oncology annual meeting in Chicago, Ill., from June 1 to 5, 2007.

These results have major implications for myeloma therapy, noted study chair Vincent Rajkumar, M.D., Mayo Clinic, Rochester, Minn. The results of this study, particularly lenalidomide plus low-dose dexamethasone, are very positive and in my opinion represent a real step forward in the treatment of this disease.

A total of 445 patients with newly diagnosed multiple myeloma, who had not previously received chemotherapy, were enrolled in this study between 2004 and 2006. Patients were randomized to one of two treatment arms. One patient group receive d lenalidomide and dexamethasone given at standard doses. The second group received standard-dose lenalidomide and low-dose dexamethasone. The primary objective was to determine if the low-dose arm would have similar response rates and lower toxicity than the standard-dose arm.

Randomized trials are the gold standard for evaluation of the effectiveness of new treatments, said NCI Director John E. Niederhuber, M.D. These results also emphasize once again the importance of NCIs rigorous program of oversight, which brings highly qualified clinician scientists to serve as members of data safety and monitoring committees.

Lenalidomide, a derivative of thalidomide, was approved by the U.S. Food and Drug Administration in 2006 to be used in combination with dexamethasone for the treatment of multiple myeloma in patients who received at least one prior therapy for their disease. Dexamethasone is a steroid that acts as an anti-inflammatory and as an immunosuppressant and has numerous uses in medical practice.

ECOG has a long history in developing new treatments for multiple myeloma, according to Robert L. Comis, M.D., ECOG group chairperson. The application of this effective and less toxic approach will benefit many patients with this disease.

Celgene, Inc., Summit, N.J., which manufactures lenalidomide, provided lenalidomide for the trial under a Cooperative Research and Development Agreement with NCI for the clinical development of lenalidomide.

Multiple myeloma is a cancer of plasma cells that are found in blood and bone marrow. In 2007, an estimated 19,900 people in the United States will be diagnosed with multiple myeloma and an estimated 10,790 people will die of the disease.

For more information about multiple myeloma, visit the NCI website at http://myeloma.cancer.gov.

For more information about cancer, please visit the NCI website at http://www.cancer.gov, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


Reference: E4A03: A Randomized Phase III Study of CC-5013 plus Dexamethasone vs. CC-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therapy for Non-responders.

CONTACT:
NCI Office of Media Relations
301-496-6641
'"/>




Related medicine technology :

1. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
2. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
3. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
4. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
7. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Gentiums Defibrotide Seen as Active in Multiple Myeloma
11. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Experts from various countries ... role of technology in innovative healthcare ... International Conference of VPS-Penn Medicine opened in Abu ... Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Culture and ... provide personalized medicine and tailor-made healthcare in disease treatment and ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
(Date:5/20/2016)... , May 20, 2016 According ... driver is the increasing demand for affordable healthcare solutions as ... steadily on the rise. In countries like the US, the ... In the US, the consumer price index inflation rate stood ... inflation rate moved up to 3.62% during the same time ...
Breaking Medicine Technology:
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... for physical disease or injury that focuses on repairing the musculoskeletal and neuromuscular ... With an emphasis on functional restoration, NYDNRehab began providing treatments for physical therapy ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades of experience, ... job, ensuring the best suited solution to meet regulatory requirements. Their professional staff ... lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... egg freezing, today announced the official relaunch of its community and education hub ... frozen eggs. Eggsurance's mission is to create a safe and welcoming place for ...
(Date:5/24/2016)... ... May 24, 2016 , ... The Radiosurgery Society ... of radiosurgery, is recognizing five medical residents and students for their outstanding contributions ... (SBRT). The awards will be presented at the 2016 SRS/SBRT Scientific Meeting taking ...
(Date:5/24/2016)... ... May 24, 2016 , ... The ... 9.3 million people, or 10% over last year, according to data in the ... group policies was comparatively stable, with a slight decrease in risk-based groups and ...
Breaking Medicine News(10 mins):